Partner/Investor Opportunities

To help us achieve the greatest impact for patients,
Pio Tx welcomes opportunities for partnering and collaborative discussions.

Current status of PIO-001 program:

  • PIO-001 specificity and epitope has been validated through solving the PIO-001/IL-21 crystal structure
  • In vitro functional assays developed in cell lines and primary lymphocytes to characterize the potency of PIO-001
  • Mechanism of action of PIO-001 determined
  • Toxicology and regulatory path for PIO-001 has been defined
  • Indication prioritization through bioinformatics analysis guided by functional and mechanistic data
  • Developed and validated non-GLP bioanalytical and biomarker assays: PIO-001 PK, PIO-001 target engagement, human IL-21, ISH/IF assay (IL-21/IL-21R RNA and CD8/CD45 protein)
  • Two humanized therapeutic lead candidates have been selected (PIO-4C00, PIO-4F00)
  • Biomarker data validating the functional and mechanistic differentiation of PIO-001 is being accrued
  • Robust IP portfolio

Further information is available under confidential terms.

Pio Tx is taking this bold new discovery to market, and is collaborating with investors, the scientific community and immunology experts to bring this idea to life.